A non-steroidal mineralocorticoid receptor antagonist
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Finerenone

Item No. 36086

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-1,6-naphthyridine-3-carboxamide
CAS Number
1050477-31-0
Synonyms
  • BAY 94-8862
Molecular Formula
C21H22N4O3
Formula Weight
378.4
Purity
≥98%
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMF: 10 mg/mlDMSO: 3 mg/mlEthanol: insolPBS (pH 7.2): insol
λmax
255 nm
SMILES
CCOC1=C2[C@@H](C3=C(C=C(C=C3)C#N)OC)C(C(N)=O)=C(NC2=C(C=N1)C)C
InChi Code
InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m0/s1
InChi Key
BTBHLEZXCOBLCY-KRWDZBQOSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $110

    Add

    10 mg

    $209

    Add

    25 mg

    $304

    Add

    50 mg

    $550

    Add
    Product Description

    Finerenone is a non-steroidal mineralocorticoid receptor antagonist (IC50 = 18 nM).1 It is selective for the mineralocorticoid receptor over glucocorticoid, progesterone, and androgen receptors (IC50s = >10,000 nM for all), as well as L-type calcium channels (IC50 = >10,000 nM). Finerenone (3 mg/kg) reduces renal vasculopathy, fibrosis, and tubular degeneration, as well as cardiac fibrosis, in a rat model of hypertension-induced end-organ damage.2 It also increases exercise capacity and prevents diastolic dysfunction in ovariectomized mice.3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Kolkhof, P., Jaisser, F., Kim, S.-Y., et al. Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: Comparison at bench and bedside. Handb. Exp. Pharmacol. 243, 271-305 (2017).

    2. Kolkhof, P., Hartmann, E., Freyberger, A., et al. Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am. J. Nephrol. 52(8), 642-652 (2021).

    3. Pieronne-Deperrois, M., Guéret, A., Djerada, Z., et al. Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice. ESC Heart Fail. 8(3), 1933-1943 (2021).